Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy

BACKGROUND: Anti-interleukin (IL)-5 monoclonal antibodies as an eosinophil-depleting strategy is well established, with Mepolizumab being the first biologic approved as an adjunct treatment for severe eosinophilic asthma. CASE PRESENTATION: A 62-year old woman diagnosed with severe eosinophilic asth...

Descripción completa

Detalles Bibliográficos
Autores principales: Mukherjee, Manali, Lim, Hui Fang, Thomas, Sruthi, Miller, Douglas, Kjarsgaard, Melanie, Tan, Bruce, Sehmi, Roma, Khalidi, Nader, Nair, Parameswaran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216532/
https://www.ncbi.nlm.nih.gov/pubmed/28070196
http://dx.doi.org/10.1186/s13223-016-0174-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216532/
https://www.ncbi.nlm.nih.gov/pubmed/28070196
http://dx.doi.org/10.1186/s13223-016-0174-5

Ejemplares similares